Page 181 - 2021_12-Haematologica-web

Letters to the Editor
Etienne Crickx,1 Sylvain Audia,2 Ailsa Robbins,3
David Boutboul,4 Thibault Comont,5 Morgane Cheminant,6 Eric Oksenhendler,4 Bertrand Godeau,1 Marc Michel1
and Matthieu Mahevas1
1Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-immunes de l’Adulte, Hôpital Henri Mondor Assistance Publique Hôpitaux de Paris, Université Paris Est Créteil, Créteil; 2Service de Médecine Interne et d’Immunologie Clinique, Centre Constitutif de Référence des Cytopénies Auto-immunes de l’Adulte, Hôpital François Mitterrand, Dijon Cedex; 3Service de Médecine Interne,Maladies Infectieuses, Immunologie Clinique, CHU Robert Debré, Reims; 4Service d'Immunologie Clinique, Hôpital Saint Louis, Paris, and Paris Université; 5Service de Médecine Interne et Immunopathologie, Institut Universitaire du Cancer Toulouse – Oncopôle, Toulouse and 6Service d’Hématologie Clinique, Hôpital Necker, Paris, France
Correspondence:
MATTHIEU MAHÉVAS - matthieu.mahevas@aphp.fr doi:10.3324/haematol.2021.279232
Received: May 16, 2021.
Accepted: July 1, 2021.
Pre-published: August 5, 2021.
Disclosures: no conflicts of interest to disclose.
Contributions: EC and MMa designed the study and analyzed the data. EC, SA, AR, TC, DB, MC, EO, MMi, BG and MMa wrote the manuscript and included patients in the study.
Acknowledgments: we thank L. Languille for logistic coordination.
References
1. Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620-632.
2. Mahévas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome, and response to therapy of multirefractory chronic
immune thrombocytopenia. Blood. 2016;128(12):1625-1630.
3. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic ane- mia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930-
2936.
4. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy
in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027): 1551-1560.
5. Jain A, Gupta DK. Daratumumab for refractory warm autoimmune hemolytic anemia. Ann Hematol. 2021;100(5):1351-1353.
6. Cooling L, Hugan S. Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient. Transfusion. 2019;59(12):3801-3802.
7. Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life- threatening autoimmune hemolytic anemia following hematopoi- etic stem cell transplantation. Blood Adv. 2018;2(19):2550-2553.
8. Blennerhassett R, Sudini L, Gottlieb D, Bhattacharyya A. Post-allo- geneic transplant Evans syndrome successfully treated with daratu- mumab. Br J Haematol. 2019;187(2):e48-e51.
9. Even-Or E, Naser Eddin A, Shadur B, et al. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer. 2020;67(1):e28010.
10.Driouk L, Schmitt R, Peters A, et al. Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature. Mol Cell Pediatr. 2021;8(1):5.
11. Zaninoni A, Giannotta JA, Gallì A, et al. The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease. Front Immunol. 2021;12:649441.
12. Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with daratu- mumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149-1155.
13. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of ter- minology, definitions and outcome criteria in immune thrombocy- topenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
14. Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017;92(1):23-27.
15. Dossier C, Prim B, Moreau C, et al. A global antiB cell strategy com- bining obinutuzumab and daratumumab in severe pediatric nephroticsyndrome.PediatrNephrol.2021;36(5):1175-1182.
haematologica | 2021; 106(12)
3201